.
MergerLinks Header Logo

Announced

Completed

Arcutis Biotherapeutics completed the acquisition of Ducentis BioTherapeutics from LifeArc for $400m.

Financials

Edit Data
Transaction Value£348m
Consideration TypeOrdinary Shares, Contingent Deferred Consideration
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United Kingdom

Acquisition

Majority

Private

Biotechnology

Completed

Friendly

biotechnology

Cross Border

Single Bidder

Synopsis

Edit

Arcutis Biotherapeutics, a California-based early commercial stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, completed the acquisition of Ducentis BioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, from LifeArc, a self-funded medical research charity, for $400m. "Arcutis has the resources, experience and commitment to accelerate clinical development of DS-234 to treat patients with atopic dermatitis, and, in future, other serious autoimmune diseases lacking effective treatment options. With Arcutis' depth of knowledge and capabilities in dermatology, and its team's experience developing, manufacturing and commercialising biologics, we are confident Arcutis is well positioned to build on Ducentis' pre-clinical work," Philip Huxley, Ducentis founder and former CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US